Vor Biopharma, a Boston, MA-based immuno-oncology company pioneering engineered hematopoietic stem cell (HSC) therapies for the treatment of hematological malignancies, raised $42m in Series A financing.
The round was led by 5AM Ventures and RA Capital Management, with participation from Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Novartis Institutes for BioMedical Research (NIBR), and Osage University Partners and Vor co-founder PureTech Health. In conjunction with the funding, Kush Parmar, M.D., Ph.D., Managing Partner at 5AM Ventures, joined the Vor Biopharma Board of Directors as Executive Chair, along with Joshua Resnick, M.D., Managing Director at RA Capital.
The company plans to use the funds to advance its lead HSC-based candidate for the treatment of acute myeloid leukemia (AML) towards the clinic, and to further build its pipeline to treat hematologic malignancies.
Co-founded by PureTech Health (LSE: PRTC) and based on the work of Siddhartha Mukherjee, M.D., D.Phil, as well as Vor’s own intellectual property, Vor is developing a proprietary pipeline of immunotherapies for patients.
The company is working with leading oncologists and immunologists including Hans-Peter Kiem, M.D., Ph.D., the Fred Hutch Endowed Chair for Cell and Gene Therapy and the Director of the Stem Cell and Gene Therapy Program at the Fred Hutchinson Cancer Research Center and a Professor of Medicine at the University of Washington School of Medicine; Dan Littman, M.D., Ph.D., the Kimmel Professor of Molecular Immunology at the Skirball Institute and an Investigator of the Howard Hughes Medical Institute at NYU Langone Health; Derrick J. Rossi, Ph.D., an Associate Professor in the Stem Cell and Regenerative Biology Department at Harvard Medical School and Harvard University; and Joseph Bolen, Ph.D., Chief Scientific Officer at PureTech Health.